| Literature DB >> 32928322 |
N J L Haw1, J Uy1,2, K T L Sy3,4, M R M Abrigo2.
Abstract
The Philippines confirmed local transmission of COVID-19 on 7 March 2020. We described the characteristics and epidemiological time-to-event distributions for laboratory-confirmed cases in the Philippines recorded up to 29 April 2020 and followed until 22 May 2020. The median age of 8212 cases was 46 years (IQR 32-61), with 46.2% being female and 68.8% living in the National Capital Region. Health care workers represented 24.7% of all detected infections. Mean length of hospitalisation for those who were discharged or died were 16.00 days (95% CI 15.48-16.54) and 7.27 days (95% CI 6.59-8.24). Mean duration of illness was 26.66 days (95% CI 26.06-27.28) and 12.61 days (95% CI 11.88-13.37) for those who recovered or died. Mean serial interval was 6.90 days (95% CI 5.81-8.41). Epidemic doubling time prior to the enhanced community quarantine (ECQ; 11 February and 19 March) was 4.86 days (95% CI 4.67-5.07) and the reproductive number was 2.41 (95% CI 2.33-2.48). During the ECQ (20 March to 9 April), doubling time was 12.97 days (95% CI 12.57-13.39) and the reproductive number was 0.89 (95% CI 0.78-1.02).Entities:
Keywords: COVID-19; Philippines; epidemiology; low- and middle-income country; surveillance
Mesh:
Year: 2020 PMID: 32928322 PMCID: PMC7506175 DOI: 10.1017/S0950268820002137
Source DB: PubMed Journal: Epidemiol Infect ISSN: 0950-2688 Impact factor: 2.451
Characteristics of COVID-19 cases in the Philippines as of 29 April 2020
| All cases ( | Died ( | Recovered ( | |
|---|---|---|---|
| Age in years, median (IQR) | 46 (32–61) | 66 (57–74) | 46 (32–59) |
| Age group, | |||
| 0–10 years old | 133 (1.6) | 7 (0.9) | 30 (1.0) |
| 11–20 years old | 186 (2.3) | 5 (0.7) | 39 (1.3) |
| 21–40 years old | 3032 (36.9) | 32 (4.2) | 1181 (39.5) |
| 41–60 years old | 2761 (33.6) | 216 (28.1) | 1049 (35.1) |
| 60–80 years old | 1884 (22.9) | 415 (54.0) | 653 (21.9) |
| 80+ years old | 210 (2.6) | 93 (12.1) | 35 (1.2) |
| Unknown | 6 (0.1) | 0 (0.0) | 1 (0.03) |
| Females, | 3791 (46.2) | 266 (34.6) | 1418 (47.5) |
| Healthcare worker, | |||
| Doctors | 614 (7.5) | 27 (3.5) | 372 (12.5) |
| Nurses | 726 (8.8) | 6 (0.8) | 369 (12.4) |
| Allied health professionals | 687 (8.4) | 2 (0.3) | 340 (11.4) |
| Unknown | 2938 (35.8) | 362 (47.1) | 465 (15.6) |
| Location, | |||
| National Capital Region (NCR) | 5649 (68.8) | 572 (74.5) | 2188 (73.2) |
| Luzon without NCR | 1726 (21.0) | 143 (18.6) | 555 (18.6) |
| Visayas | 623 (7.6) | 24 (3.1) | 110 (3.7) |
| Mindanao | 182 (2.2) | 29 (3.8) | 132 (4.4) |
| Unknown | 32 (0.4) | 0 (0.0) | 0 (0.0) |
| Travel history within 14 days prior to onset of symptoms, | |||
| Foreign country with local transmission | 276 (3.4) | 23 (3.0) | 175 (5.9) |
| No foreign travel | 5709 (69.5) | 562 (73.2) | 2561 (85.7) |
| Unknown | 2227 (27.1) | 183 (23.8) | 252 (8.4) |
| Comorbidities, | |||
| Hypertension | 1468 (17.9) | 264 (34.4) | 723 (24.2) |
| Diabetes | 1045 (12.7) | 217 (28.3) | 499 (16.7) |
| Renal disease | 183 (2.2) | 53 (6.9) | 63 (2.1) |
| Cardiovascular disease | 263 (3.2) | 92 (12.0) | 113 (3.8) |
| Cancer | 79 (1.0) | 18 (2.3) | 33 (1.1) |
| COPD | 36 (0.4) | 12 (1.6) | 13 (0.4) |
| Tuberculosis | 83 (1.0) | 17 (2.2) | 35 (1.2) |
| Asthma | 263 (3.2) | 22 (2.9) | 146 (4.9) |
| Unknown | 4301 (52.4) | 269 (35.0) | 1045 (35.0) |
| Signs and symptoms, | |||
| Fever | 2573 (31.3) | 363 (47.3) | 1270 (42.5) |
| Cough | 3689 (44.9) | 463 (60.3) | 1731 (57.9) |
| Difficulty breathing | 1806 (22.0) | 416 (54.2) | 737 (24.7) |
| Sore throat | 1638 (20.0) | 83 (10.8) | 847 (28.4) |
| Diarrhoea | 584 (7.1) | 43 (5.6) | 321 (10.7) |
| Unknown | 3188 (38.8) | 79 (14.2) | 44 (4.3) |
Fig. 1.Onset of illness among the first 8212 COVID-19 cases in the Philippines, the National Capital Region, and Region 7.
Fig. 2.Time-to-Event Distributions for key epidemiologic events and surveillance delays. (a) Serial interval or the time between onset of symptoms for index and secondary cases. (b) Behavioural delay or time between symptom onset to first medical consultation. (c) Diagnostic delay or time between illness onset to laboratory confirmation for COVID-19. (d) Length of stay or time from hospitalisation to discharge (blue) or death (red). (e) Length of condition or time from symptom onset to recovery (blue) or death (red). (f) Reporting delay or time between laboratory confirmation to public announcement by DOH.
Fig. 3.Some known large Covid-19 outbreak clusters in the Philippines.